6 completed, 2 terminated, 1 unknown. 9 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 6, Terminated 2, Unknown 1 |
| Phase 1 | 2 | Completed 2 |
| Phase 3 | 1 | Completed 1 |
Follow Anidulafungin: new trials by email Literature Review of Anidulafungin trials Research Report on Anidulafungin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pharmacokinetics of Anidulafungin (Ecalta ®) Intravenous Given to Patients at High Risk for Developing Invasive Fungal Disease anidulafungin 200 mg q48h, anidulafungin 300 mg q72h - Leukemia, Myelodysplastic Syndrome | Phase 2 | Completed | Radboud University Medical Center | 26 | 2010-11-01 | 2020-12-08 |
| Candida in the Respiratory Tract Secretions of Critically Ill Patients and The Efficacy of Antifungal Treatment Normal Saline, anidulafungin - Ventilator Associated Pneumonia, Respiratory Tract Infection | Phase 2 | Terminated | Daren K. Heyland | 61 | 2010-04-01 | 2021-02-01 |
| Anidulafungin in Patients With Hematologic Malignancies Anidulafungin - Hematologic Malignancies | Phase 2 | Terminated | Elisabethinen Hospital | 10 | 2009-10-01 | 2012-03-02 |
| Anidulafungin During Continuous Venovenous Hemofiltration (CVVHF) Anidulafungin - Acute Renal Failure, Infection | Phase 2 | Unknown | Medical University of Vienna | 10 | 2009-04-01 | 2009-05-04 |
| Anidulafungin in Treating Immunocompromised Children With Neutropenia anidulafungin - Infection, Neutropenia | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 2003-07-01 | 2013-06-19 | |
| Safety, Tolerance and Pharmacokinetics of Anidulafungin in Immunocompromised Children Ages 2-17 Anidulafungin - Neutropenia | Phase 1 / Phase 2 | Completed | Pfizer | 25 | 2003-07-01 | 2008-10-21 |
| The Safety and Efficacy of Intravenous Anidulafungin as a Treatment for Azole-Refractory Mucosal Candidiasis (FRMC) Anidulafungin, VER002 - Candidiasis | Phase 2 | Completed | Pfizer | 19 | 2002-08-01 | 2008-10-20 |
| A Safety & Effectiveness Study of Intravenous Anidulafungin With AmBisome® for Treatment of Invasive Aspergillosis (IA). Anidulafungin, VER002 - Aspergillosis | Phase 2 / Phase 3 | Completed | Pfizer | 30 | 2002-05-01 | 2008-10-21 |
| The Safety and Effectiveness of Intravenous Anidulafungin as a Treatment for Patients With Invasive Candidiasis. Anidulafungin, VER002 - Candidiasis | Phase 2 | Completed | Pfizer | 120 | 2001-08-01 | 2008-10-21 |
Candidiasis (2) · Candidiasis, Invasive (2) · Infections (2) · Neutropenia (2) · Acute Kidney Injury (1) · Aspergillosis (1) · Candidemia (1) · Febrile Neutropenia (1) · Fever (1) · Hematologic Neoplasms (1) · Invasive Fungal Infections (1) · Leukemia (1) · Leukemia, Myeloid, Acute (1) · Myelodysplastic Syndromes (1) · Pneumonia, Ventilator-Associated (1)
Pfizer (4) · Daren K. Heyland (1) · Elisabethinen Hospital (1) · Medical University of Vienna (1) · National Cancer Institute (NCI) (1) · Radboud University Medical Center (1)
United States (5) · Austria (2) · Canada (1) · Netherlands (1)
Daren Heyland, MD (1) · Michael Girschikofsky, MD (1) · Thomas J. Walsh, MD (1)
PMID 21287306, PMID 24981955, PMID 25473029
2009 (1)